公开(公告)号：US20210230591A1

公开(公告)日：2021-07-29

申请号：US17091293

申请日：2020-11-06

申请人： Aligos Therapeutics, Inc.

发明人： Chia-Cheng Kao ,  Lawrence M. Blatt ,  Leonid Beigelman

IPC分类号： C12N15/113

摘要： Methods of reducing levels of virus molecules and/or treating viral infections include contacting cells with an oligonucleotide inhibitor that targets a cellular host factor that is a target RNA or target protein involved in viral replication. A pharmaceutical composition can include such an oligonucleotide inhibitor in an amount effective for treating an infection, such as a hepatitis B infection or a respiratory virus infection, such as a coronavirus infection.

公开(公告)号：US11613750B2

公开(公告)日：2023-03-28

申请号：US17091293

申请日：2020-11-06

申请人： Aligos Therapeutics, Inc.

发明人： Chia-Cheng Kao ,  Lawrence M. Blatt ,  Leonid Beigelman

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N15/113

摘要： Methods of reducing levels of virus molecules and/or treating viral infections include contacting cells with an oligonucleotide inhibitor that targets a cellular host factor that is a target RNA or target protein involved in viral replication. A pharmaceutical composition can include such an oligonucleotide inhibitor in an amount effective for treating an infection, such as a hepatitis B infection or a respiratory virus infection, such as a coronavirus infection.

公开(公告)号：US20210189392A1

公开(公告)日：2021-06-24

申请号：US17117494

申请日：2020-12-10

申请人： Aligos Therapeutics, Inc.

发明人： Leonid Beigelman ,  Rajendra Pandey ,  Vivek Kumar Rajwanshi ,  David Bernard Smith ,  Lawrence M. Blatt ,  Jin Hong ,  Megan Elizabeth Fitzgerald

IPC分类号： C12N15/113

摘要： Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

公开(公告)号：US20220160748A1

公开(公告)日：2022-05-26

申请号：US17455528

申请日：2021-11-18

申请人： Aligos Therapeutics, Inc.

发明人： Leonid Beigelman ,  Megan Elizabeth Fitzgerald ,  Rajendra Pandey ,  Jin Hong ,  Vivek Kumar Rajwanshi ,  David Bernard Smith ,  Lawrence M. Blatt

IPC分类号： A61K31/7088 ,  A61K47/54 ,  A61P1/16

摘要： Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3′ end and/or a 5′ end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.

公开(公告)号：US20220125825A1

公开(公告)日：2022-04-28

申请号：US17511366

申请日：2021-10-26

申请人： ALIGOS THERAPEUTICS, INC.

发明人： Leonid Beigelman ,  Rajendra Pandey ,  Vivek Kumar Rajwanshi ,  David Bernard Smith ,  Lawrence M. Blatt ,  Jin Hong

IPC分类号： A61K31/7125 ,  A61K9/00 ,  A61P31/20 ,  C12N15/113 ,  C07H21/02

摘要： Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.

公开(公告)号：US11166976B2

公开(公告)日：2021-11-09

申请号：US17018822

申请日：2020-09-11

申请人： ALIGOS THERAPEUTICS, INC.

发明人： Leonid Beigelman ,  Rajendra Pandey ,  Vivek Kumar Rajwanshi ,  David Bernard Smith ,  Lawrence M. Blatt ,  Jin Hong

IPC分类号： A61K31/7125 ,  A61K9/00 ,  A61P31/20 ,  C12N15/113 ,  C07H21/02

摘要： Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.

公开(公告)号：US20200147124A1

公开(公告)日：2020-05-14

申请号：US16676929

申请日：2019-11-07

申请人： ALIGOS THERAPEUTICS, INC.

发明人： Leonid Beigelman ,  Rajendra Pandey ,  Vivek Kumar Rajwanshi ,  David Bernard Smith ,  Lawrence M. Blatt ,  Jin Hong

IPC分类号： A61K31/7115 ,  A61K9/00 ,  A61P31/20 ,  A61K45/06 ,  C12N15/113 ,  C07H21/02

摘要： Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.